Navigation Links
SynCo Bio Partners and Versartis Expand Collaboration as Lead Product Enters into Clinical Trials
Date:7/29/2010

AMSTERDAM, July 29, 2010 /PRNewswire/ -- SynCo Bio Partners today announced an extension of its successful collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis' lead product VRS-859 (exenatide-XTEN).

Under the extended agreement, SynCo will scale-up a second manufacturing process on behalf of Versartis, this time in preparation for the GMP manufacture of VRS-317, a once monthly form of human growth hormone for the treatment of children and adults with growth hormone deficiency. As with the VRS-859 program, SynCo will also provide fill and finish services for the manufacture, testing and release of formulated Drug Product vials. SynCo completed process development and optimization, scale-up and GMP manufacture of VRS-859 for Phase 1 clinical studies earlier this year.

"Versartis achieved its first major clinical milestone, a Phase 1 trial of VRS-859, in just over one year after Series A demonstrating our ability to efficiently and quickly execute our development plans," said Jeffrey L. Cleland, Ph.D., Versartis' Chief Executive Officer. "The strength and commitment of our collaborators, such as SynCo Bio Partners, is a key factor in this achievement and we look forward to a similarly successful partnership for our second product, VRS-317."

Pierre Warffemius, SynCo Bio Partners Chief Executive Officer stated, "SynCo is extremely proud of its success in supporting Versartis to progress its pipeline. The VRS-859 manufacturing program was completed on time due to the combined expertise and
'/>"/>

SOURCE SynCo Bio Partners B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
2. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
3. SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
4. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
5. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
6. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
7. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
8. Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation
9. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
10. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
11. Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... that it will hold its 2015 Annual Meeting of ... Because the expected date for the Annual Meeting ...
(Date:12/24/2014)... BOSTON, MA (PRWEB) December 23, 2014 ... generation webinar series is designed to introduce ... and inform users and partners of platform ... features and benefits; empowering users in their ... and powerful tools. , According to SoundConnect’s ...
(Date:12/24/2014)... 23, 2014 Nashville Fertility Center announced ... treasurer for the American Society for Reproductive Medicine (ASRM), ... research in reproductive medicine. In his new role ... the executive board and will have a voice in ... has actively supported ASRM since 1984 when he joined ...
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... - - ... -, SOUTH SAN FRANCISCO, Calif., Aug. 17 ... U.S. Food and Drug,Administration (FDA) has approved Zingo(TM) (lidocaine ... analgesia to reduce the pain associated with venous access,procedures, ...
... (Nasdaq: IDEV ) today announced that it ... and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a sterile ... product approved by the FDA for therapy of,bacillus ... bladder. VALSTAR was removed from the market ...
... Union announced today they,have entered into a five-year ... in Region 3 to provide RealTime1(TM) (RT1(TM)),software at ... and the,US Virgin Islands. The Region 3 Genetics ... funding for another five-year period.,With this renewal, Region ...
Cached Biology Technology:Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 3Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 4Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 5Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Digital Union's RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative 2
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... renowned climate researcher Caroline Leck of Stockholm University has ... results are truly sensational," says Dr Leck. "If confirmed ... efforts to achieve the political targets for climate." ... Earth,s mean surface temperature climbed sharply through the 1990s, ...
... one of the leaders in the field of neurosciences, ... of one of literature,s greatest authors, Virginia Woolf. The ... the literature she wrote and comments, letters and other ... medical status. The author uses current insights into depression, ...
... 25, 2013 /PRNewswire-iReach/ --   Find Heather on ... . She is a a third year physics major at the ... also learned after writing numerous twenty plus page lab reports, a life ... a career relating to patents and IP law. Last summer, she interned ...
Cached Biology News:Global warming less extreme than feared? 2Global warming less extreme than feared? 3Global warming less extreme than feared? 4The Website You Have to Log Into 2The Website You Have to Log Into 3